Morbid Progression Is Common Among Patients with Multiple Myeloma and Is Associated with Shortened Overall Survival: Validation of the Progression-Free Survival Endpoint

被引:0
|
作者
Rosenberg, Aaron Seth
Facon, Thierry
Abouzaid, Safiya
Srinivasan, Shankar
Chung, Weiyuan
Parikh, Kejal
Tuscano, Joseph
机构
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
3113
引用
收藏
页数:3
相关论文
共 50 条
  • [1] Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint
    Rosenberg, Aaron S.
    Facon, Thierry
    Parikh, Kejal
    Chung, Weiyuan
    Srinivasan, Shankar
    Kotey, Stanley
    Tuscano, Joseph
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (05): : 345 - +
  • [2] Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos M.
    Sonneveld P.
    Manier S.
    Lam A.
    Roccia T.
    Schecter J.M.
    Cost P.
    Pacaud L.
    Poirier A.
    Tremblay G.
    Lan T.
    Valluri S.
    Kumar S.
    [J]. BMC Cancer, 24 (1)
  • [3] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M.
    Sonneveld, P.
    Nahi, H.
    Kumar, S.
    Hashim, M.
    Kulakova, M.
    Duran, M.
    Heeg, B.
    Lam, A.
    Dearden, L.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A408 - A408
  • [4] Impact of Race on Progression-Free Survival and Overall Survival in Patients with Multiple Myeloma
    Wani, Kashmira
    Gutta, Radhika
    Mittal, Aayush
    Jamil, Maria
    Springer, Kylie
    Kuriakose, Philip
    [J]. BLOOD, 2023, 142
  • [5] Soluble MICA as a prognostic factor for the overall survival and progression-free survival of multiple myeloma patients
    Rebmann, V.
    Schuett, P.
    Brandhorst, D.
    Opalka, B.
    Nowrousian, M. R.
    Moritz, T.
    Grosse-Wilde, H.
    [J]. TISSUE ANTIGENS, 2007, 69 (05): : 390 - 390
  • [6] Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
    Cicero, Giuseppe
    De Luca, Rossella
    Dieli, Francesco
    [J]. ONCOTARGETS AND THERAPY, 2018, 11 : 3059 - 3063
  • [7] Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients
    Rebmann, Vera
    Schuett, Philipp
    Brandhorst, Dieter
    Opalka, Bertram
    Moritz, Thomas
    Nowrousian, Mohammad Reza
    Grosse-Wilde, Hans
    [J]. CLINICAL IMMUNOLOGY, 2007, 123 (01) : 114 - 120
  • [8] Immunoglobulin Recovery after ASCT for Patients with Multiple Myeloma: Impact on Overall Survival and Progression-Free Survival
    Jimenez-Zepeda, Victor
    Duggan, Peter
    Neri, Paola
    Chaudhry, Ahsan
    Tay, Jason
    Bahlis, Nizar J.
    [J]. BLOOD, 2016, 128 (22)
  • [9] Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations
    Johnson, David C.
    Gregory, Walter M.
    Dickens, Nicholas J.
    Walker, Brian A.
    Szubert, Alex J.
    Davies, Faith E.
    Durie, Brian G. M.
    Van Ness, Brian G.
    Morgan, Gareth J.
    [J]. BLOOD, 2009, 114 (22) : 177 - 177
  • [10] Progression-Free Survival as a Surrogate Endpoint of Overall Survival in Patients With Metastatic Renal Cell Carcinoma
    Halabi, Susan
    Rini, Brian
    Escudier, Bernard
    Stadler, Walter M.
    Small, Eric J.
    [J]. CANCER, 2014, 120 (01) : 52 - 60